U.S. markets closed

ScinoPharm Taiwan, Ltd. (1789.TW)

Taiwan - Taiwan Delayed Price. Currency in TWD
24.50-0.40 (-1.61%)
As of 12:04PM CST. Market open.

ScinoPharm Taiwan, Ltd.

No. 1, Nan-Ke 8th Road
Southern Taiwan Science Park Shan-Hua
Tainan City 74144
886 6 505 2888

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Chih-Hsien LoChairman & Gen. Chief Strategy OfficerN/AN/A1957
Ms. Li-An LuPres & CEON/AN/AN/A
Ms. Chih-Hui LinActing Financial Off., Sr. Director of Acct., Acct. Off., Acting Spokesperson & Corp. Gov. Off.N/AN/AN/A
Mr. Ling-Hsiao LienVice-Pres of OperationsN/AN/AN/A
Dr. Li-Chiao Chang Chemistry, Ph.D.VP of R&D Division and Chief Scientific OfficerN/AN/AN/A
Mr. Jason ChenDirector of HR & AdminN/AN/AN/A
Dr. Ching-Wen Lin B.S, M.S, Ph.D.VP of Marketing & Sales and Chief Strategy OfficerN/AN/AN/A
Mr. Shun Yang LinDirector of Corp. Devel.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.


ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, it develops and manufactures western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.

Corporate Governance

ScinoPharm Taiwan, Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.